Revenue grew 38% year-over-year to $1.67B, driven by strong product demand and a one-time CMS benefit. Guidance for 2026 was raised across net sales and key franchises, with Opzelura and hematology/oncology segments showing robust growth.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.